No Data
No Data
Kingchem (Liaoning) Life Science Co., Ltd.'s (SZSE:301509) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
26.6293 million restricted shares of Jinkai Bioengineering (301509.SZ) will be listed for circulation on August 7th.
Jinkai Life Science (301509.SZ) announced that the restricted shares applied for sale by the company this time are the shares that were not publicly issued before ...
As of July 31, there were 12,785 shareholders in GeneScience Pharmaceuticals (301509.SZ).
Jinkai Life Science (301509.SZ) stated on the investor interaction platform on August 2 that as of July 31, 2024, the number of shareholders of the company is 12,785.
Jinkai Biosciences (301509.SZ): In the field of oral polypeptide projects, the company focuses on the process development and production services of SNAC intermediates.
On August 2nd, Gelunhui reported that Jinkai Life Sciences (301509.SZ) stated on its investor interaction platform that the company's existing fluorination production capacity includes special fluorination agents (such as sulfur tetrafluoride, pyridine hydrofluoride, hydrogen fluoride triethylamine), hydrogen fluoride fluorination, potassium fluoride fluorination, electrolytic fluorination, etc.; in terms of oral peptide projects, the company focuses on the process development and production services of SNAC intermediates.
As of July 19, 2024, there are 12,820 shareholders of Jinkai Life Sciences (301509.SZ) Company.
On July 23rd, Gelunhui reported that as of July 19th, 2024, there were 12,820 shareholders in Jinkai Life Science (301509.SZ) according to the investor communication platform.
Jinkai Life Science (301509.SZ): currently, the proportion of unrestricted circulating shares is 25%, and it does not meet the repurchase requirements.
On July 19th, Gelunhui reported that Jinkai Life Science (301509.SZ) stated on the investor interaction platform that the company's unrestricted circulating shares accounted for 25% and did not have the conditions for repurchase. However, the company has always attached importance to returning shareholders. We will closely monitor market dynamics, comprehensively evaluate the company's financial and cash flow status, and future global strategic development needs. If the company has a corresponding plan to repurchase shares in the future, we will fulfill our disclosure obligations in a timely manner.
No Data